The only international event dedicated to discussing regulatory, ethical and operational aspects of running clinical trials in Russia

26-27 November 2019

InterContinental Moscow Tverskaya Hotel

First speaker confirmations in 2019

Victoria Kosmacheva, Clinical Research Director, Non-Foot Print Countries, GSK
Victoria Kosmacheva

Clinical Research Director, Non-Foot Print Countries

GSK

Sergey Dubrovin, Director of Clinical Site Management, Russia and Belarus, Pfizer
Sergey Dubrovin

Director of Clinical Site Management, Russia and Belarus

Pfizer

Ksenia Teplova-Bareysha, Country Head of Site Management, Bayer
Ksenia Teplova-Bareysha

Country Head of Site Management

Bayer

Mikhail Samsonov, Chief Medical Officer, R-Pharm
Mikhail Samsonov

Chief Medical Officer

R-Pharm

Konstantin Gudkov, Clinical Research Director, AstraZeneca Russia
Konstantin Gudkov

Clinical Research Director

AstraZeneca Russia

Olga Melnik, Head of Clinical Operations, Novartis Pharma
Olga Melnik

Head of Clinical Operations

Novartis Pharma

Marina Debryanskaya, Head of Clinical Trials Management, Russian Innovation Centre, Takeda Pharmaceuticals
Marina Debryanskaya

Head of Clinical Trials Management, Russian Innovation Centre

Takeda Pharmaceuticals

Alexander Andreev, Clinical Trials Director in the EEU countries, Servier
Alexander Andreev

Clinical Trials Director in the EEU countries

Servier

Roman Drai, Director, Clinical Development, GEROPHARM
Roman Drai

Director, Clinical Development

GEROPHARM

Andrei Khitriy, Head of Biostatistics, Synergy Research Group
Andrei Khitriy

Head of Biostatistics

Synergy Research Group

Vladimir Vasilyev, Compliance Process, Training & Systems Manager, PDG Country Clinical Operations, CEETRISMEA, F.Hoffmann-La Roche Ltd.
Vladimir Vasilyev

Compliance Process, Training & Systems Manager, PDG Country Clinical Operations, CEETRISMEA

F.Hoffmann-La Roche Ltd.

Yuri Zhulev, Co-Chairman, Russian Patients Association
Yuri Zhulev

Co-Chairman

Russian Patients Association

Mikhail Maschan, Director of High School of Molecular and Experimental Medicine, Dmitry Rogachev National Research Center
Mikhail Maschan

Director of High School of Molecular and Experimental Medicine

Dmitry Rogachev National Research Center

Nikolay Zhukov, Head of the Department for Optimization of Treatment for Adolescents and Young Adults with Oncological Diseases, Rogachev Federal Scientific and Clinical Centre of Pediatric Hematology Oncology and Immunology
Nikolay Zhukov

Head of the Department for Optimization of Treatment for Adolescents and Young Adults with Oncological Diseases

Rogachev Federal Scientific and Clinical Centre of Pediatric Hematology Oncology and Immunology

Tatiana Zhiganova, Head of Translational and Cell Research Department, Rogachev Federal Scientific and Clinical Centre of Pediatric Hematology Oncology and Immunology
Tatiana Zhiganova

Head of Translational and Cell Research Department

Rogachev Federal Scientific and Clinical Centre of Pediatric Hematology Oncology and Immunology

Natalia Krasnopeyeva, Endocrinologist, Russian Railways Clinical Hospital, Chelyabinsk
Natalia Krasnopeyeva

Endocrinologist

Russian Railways Clinical Hospital, Chelyabinsk

Olga Bolshakova, Head, Scientific Research Laboratory of Clinical Trials and Evidence-Based Medicines of Preclinical and Clinical Research Centre, Almazov National Medical Research Centre
Olga Bolshakova

Head, Scientific Research Laboratory of Clinical Trials and Evidence-Based Medicines of Preclinical and Clinical Research Centre

Almazov National Medical Research Centre

Topics for discussion in 2019

• Future of clinical trials: development trends globally and in Russia
• Clinical trials in the Eurasian Economic Union: common rules in action
• Digitalization in clinical trials: AI, portable devices, electronic registers, switch to electronic patient consent
• Improving quality of clinical studies: point of view of various stakeholder groups
• Patient engagement in clinical trials
• Early access for medicines to the market: features of early phases of clinical trials
• Non-interventional post-registration studies: development trends
• Investigator initiated clinical trials: distinguishing features, challenges and opportunities
• Biostatistics and data management
• Clinical trials of pharmaceutical drugs for rare diseases: ways to improve effectiveness
• Clinical trials of gene and cell therapy drugs: what to expect?
• Clinical trials of drugs used in life-threatening diseases
• Collaboration between a sponsor and investigator centres: transformation in the era of technological changes

Why to attend the Clinical Trials in Russia Forum in 2019?

adamsmith 14october2018 049

Insights from 40+ experts: regulators, representatives of international and Russian pharmaceutical producers, CROs and investigators

adamsmith 13october2018 206

2-day information-rich programme that includes insightful presentations from leading sector players, interactive debates and round tables

adamsmith 13october2018 086

Unrivalled networking opportunities with 150+ attendees from such companies as AstraZeneca, Pfizer, Novartis, Bayer, Biocad, R-Pharm and many more

FEEDBACK FROM ATTENDEES

Unique opportunity for all the clinical trials sector players to meet and discuss the most burning issues.

Tatiana Minakova,

Associate Director, Clinical Monitoring, Syneos Health

The forum brings together representatives of all stakeholder groups involved in clinical trials – sponsors, CROs, regulators and investigators for a constructive dialogue aimed at improving all future processes.

Julia Semenova,

Pharma Development Unit Head, Novartis Russia

Very good overview of a large number of clinical trial topics and the specifics of the Russian market.

Henryette Schatt,

JDirector eCOA Business Development, ERT (Switzerland)

Very interesting insight into the latest developments in the Russian market.

Stefanie Rau,

Clinical Trials and Pharmacovigilance Manager Europe, MUCOS Pharma (Germany)


Sponsored by:

Supporting organisations & media